Acorda Therapeutics, Inc.

Jennifer Iaci

Anthony O Caggiano

Andrea M Vecchione

Elliott A Gruskin

Gargi Roy

Sarah J Kasperbauer

Elizabeth Markensohn

Tom Parry

Anindita Ganguly

Elizabeth Hunter

Anthony J Bella

Michael P Zimber

The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.

Compositions and methods for treatment during non-acute periods following CNS neurological injury

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Compositions and methods of using chondroitinase ABCI mutants

The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Compositions and methods for promoting neuronal outgrowth

Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.

Use of a neuregulin to treat peripheral nerve injury

This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

Growing community of inventors

Boonton, NJ, United States of America

Jennifer Iaci